Compare KLA Corp. (KLAC) vs Eli Lilly And Co (LLY) Price & Performance

KLA Corporation (KLAC) trades at $207.82, down 2.32% amid a semiconductor sector correction. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.94 versus $0.917 expected, and robust profitability with a 35.66% net margin. Technical indicators signal bearish momentum with key support at $200, while analyst consensus remains bullish with a $243.43 price target. Recent corporate actions include a 1:10 stock split effective June 12, 2026, and a $2.30 dividend paid June 2, 2026.

KLAC's outlook is supported by dominant market positioning in semiconductor process control and AI-driven demand, but high valuation multiples (P/E 60.25) and sector volatility present risks. The stock offers growth potential through semiconductor equipment expansion, though investors should monitor industry cyclicality and competitive pressures from peers like Applied Materials.

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.